Patents Represented by Attorney, Agent or Law Firm Amy E. Mandragouras
  • Patent number: 6824779
    Abstract: The present invention relates to, inter alia, methods for inhibiting the interaction of the B-lymphocyte antigen, B7-2, with its natural ligand on the surface of an immune cell are disclosed. The methods comprise contacting the immune cell with an agent which inhibits B7-2 binding with its natural ligand, to thereby inhibit the interaction. Examples of such agents are provided, and include a soluble form of B7-2, an antibody that recognized B7-2. The method may also include contacting the immune cell with an agent that blocks the interaction of B7-1 with its natural ligand. Further, the method may include contacting the immune cell with an immunomodulating agent, for example, an antibody reactive with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug. Both in vivo and in vitro applications of the method are disclosed.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: November 30, 2004
    Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
    Inventors: Gordon J. Freeman, Lee M. Nadler, Gary S. Gray
  • Patent number: 6794147
    Abstract: An animal, e.g., transgenic mouse, in which the MSH4 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: September 21, 2004
    Assignees: Wyeth, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jeffrey W. Pollard, Winfried Edelmann, Paula E. Cohen, Burkhard Kneitz, Panos Stevis, Raju S. Kucherlapati
  • Patent number: 6689581
    Abstract: The invention provides isolated nucleic acids molecules, designated PCIP nucleic acid molecules, which encode proteins that bind potassium channels and modulate potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PCIP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PCIP gene has been introduced or disrupted. The invention still further provides isolated PCIP proteins, fusion proteins, antigenic peptides and anti-PCIP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: February 10, 2004
    Assignees: Wyeth, Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth Rhodes, Maria Betty, Huai-Ping Ling, Wenqian An
  • Patent number: 6653444
    Abstract: Isolated nucleic acid molecules encoding a B cell activation antigen, B7, are provided. In one embodiment, the nucleic acid molecules are DNA sequences. The DNA sequences of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also provided are host cells transformed to produce proteins or peptides encoded by the DNA molecules of the present invention and purified proteins and peptides which comprise at least a portion of the B cell activation antigen. The proteins and peptides comprise at least a portion of the mature form of the B7 activation antigen and preferably comprise a soluble form of the B7 protein.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 25, 2003
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Arnold S. Freedman, Lee M. Nadler
  • Patent number: 6613327
    Abstract: Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated costimulatory signal in a T cell such that spontaneous abortion in the subject is inhibited. The subject methods are also based on the levels of adhesion molecules, inflammatory cytokines, and immune cell surface molecules which are altered in spontaneous abortion.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: September 2, 2003
    Assignee: Genetics Institute, Inc.
    Inventors: Vincent Ling, Gary S. Gray, James C. Keith, Srinivas Maganti
  • Patent number: 6569667
    Abstract: The invention provides isolated nucleic acid molecules, designated DHY nucleic acid molecules, which encode novel DHY-related dehydratase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHY nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHY gene has been introduced or disrupted. The invention still further provides isolated DHY proteins, fusion proteins, antigenic peptides and anti-DHY antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: May 27, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rachel Meyers
  • Patent number: 6525178
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: February 25, 2003
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6521420
    Abstract: The invention provides isolated nucleic acids molecules, designated HATF-1 and HRP-1 nucleic acid molecules, which are differentially expressed in hypertensive humans, rats, and mice. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HATF-1 or HRP-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an HATF-1 or HRP-1 gene has been introduced or disrupted. The invention still further provides isolated HATF-1 and HRP-1 proteins, fusion proteins, antigenic peptides and anti-HATF-1 and anti-HRP-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: February 18, 2003
    Assignee: Trustees of Tufts College
    Inventors: Ira M. Herman, Greg J. Sieczkiewicz
  • Patent number: 6518398
    Abstract: The invention provides isolated nucleic acids molecules, designated ERG-LP nucleic acid molecules, which encode proteins involved in potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ERG-LP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ERG-LP gene has been introduced or disrupted. The invention still further provides isolated ERG-LP proteins, fusion proteins, antigenic pertides and anti-ERG-LP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: February 11, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rory A. J. Curtis
  • Patent number: 6500657
    Abstract: The invention provides isolated nucleic acids molecules, designated HYDL-1 nucleic acid molecules, which encode novel hydrolase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HYDL-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an HYDL-1 gene has been introduced or disrupted. The invention still further provides isolated HYDL-1 proteins, fusion proteins, antigenic peptides and anti-HYDL-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: December 31, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Alexandra Glucksmann, Rachel Meyers, Mark Williamson
  • Patent number: 6500654
    Abstract: The invention provides isolated nucleic acids molecules, designated CARK nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CARK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CARK gene has been introduced or disrupted. The invention still further provides isolated CARK proteins, fusion proteins, antigenic peptides and anti-CARK antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: December 31, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Jeyaseelan Raju
  • Patent number: 6475778
    Abstract: The present invention relates to novel SH3 domain binding protein, referred to herein a DEF polypeptides. The DEF polypeptides comprise several motifs including a src SH3 consensus binding sequence, four ankyrin repeats, one zinc finger domain and six copies of a proline-rich tandem repeat. DEF polypeptides may function as mediators of SH3 domain-dependent signal transduction pathways and, thus may mediate multiple signaling events such as cellular gene expression, cytoskeletal architecture, protein trafficking and endocytosis, cell adhesion, migration, proliferation and differentiation. Described herein are isolated and antisense nucleic acids molecules, recombinant expression vectors, host cells and non-human transgenic animals containing an insertion or a disruption of the DEF gene.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: November 5, 2002
    Assignee: Dana-Farber Cancer Institute
    Inventors: Thomas M. Roberts, Frederick J. King, David F. Harris, Erding Hu, Bruce Spiegelman, Joanne Chan
  • Patent number: 6465232
    Abstract: The invention provides isolated nucleic acids molecules, designated Kinase and Phosphatase nucleic acid molecules, which encode novel protein kinase and protein phosphatase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Kinase and Phosphatase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Kinase and Phosphatase gene has been introduced or disrupted. The invention still further provides isolated Kinase and Phosphatase proteins, fusion proteins, antigenic peptides and anti-Kinase and Phosphatase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: October 15, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Patent number: 6448005
    Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: September 10, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Alexandra Glucksmann, Fong-Ying Tsai
  • Patent number: 6444873
    Abstract: An animal, e.g., transgenic mouse, in which the MSH5 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: September 3, 2002
    Assignees: Albert Einstein College of Medicine of Yeshiva University, Dana-Farber Cancer Institute, Inc.
    Inventors: Winfried Edelmann, Richard D. Kolodner, Jeffrey W. Pollard, Raju S. Kucherlapati
  • Patent number: 6436685
    Abstract: The invention provides isolated nucleic acid molecules, designated CSAPTP nucleic acid molecules, which encode novel protein tyrosine phosphatases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPTP nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for producing CSAPTP polypeptides.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: August 20, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan L. Acton
  • Patent number: 6403767
    Abstract: The present invention provides novel D6 polypeptides and proteins, as well as isolated D6 fusion proteins, antigenic peptides and anti-D6 antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: June 11, 2002
    Assignees: Millenium Pharmaceuticals, Inc., CRC Technology Limited
    Inventors: Gerard J. Graham, Robert J. Benjamin Nibbs, Jose-Angel Gonzalo, Jose-Carlos Gutierrez-Ramos
  • Patent number: 6399760
    Abstract: The present invention, which is based on the discovery of novel genes encoding rp polypeptides, features therapeutics, diagnostics and screening assays.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: June 4, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Patrick W. Kleyn, Karen J. Moore
  • Patent number: 6395877
    Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: May 28, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Alexandra Glucksmann, Fong-Ying Tsai
  • Patent number: 6369197
    Abstract: The invention provides isolated nucleic acids molecules, designated PCIP nucleic acid molecules, which encode proteins that bind potassium channels and modulate potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PCIP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PCIP gene has been introduced or disrupted. The invention still further provides isolated PCIP proteins, fusion proteins, antigenic peptides and anti-PCIP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: April 9, 2002
    Assignees: Millennium Pharmaceuticals, Inc., American Home Products Corp.
    Inventors: Kenneth Rhodes, Maria Betty, Huai-Ping Ling, Wengian An